AOD-9604 in Longcheng — Fat Loss Peptide Research Guide
AOD-9604 research guide for Longcheng. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers seeking out AOD-9604 in Longcheng immediately realize that local retail options are all but absent from local stores. The practical advantage of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than local retail ever could. What genuinely separates top AOD-9604 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. Use this guide to evaluate AOD-9604 vendors rigorously — the quality evaluation approach outlined here work regardless of your location.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Longcheng comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger severe inflammatory responses even at trace quantities. For Longcheng researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is the accepted approach among experienced researchers. For Longcheng researchers making a first AOD-9604 purchase: verify the vendor against this framework, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Longcheng
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and small-scale human observations. Reconstitute AOD-9604 with bacteriostatic water at the concentration suited to your research design; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. The main safety concern arising from sourcing in AOD-9604 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
